07:00 AM EDT, 10/18/2024 (MT Newswires) -- Novo Nordisk's ( NVO ) pending acquisition of Catalent ( CTLT ) is facing a roadblock after US consumer groups and two large labor unions urged regulators to block the deal, citing competition concerns.

In a letter to the US Federal Trade Commission on Thursday, the US Public Interest Research Group, Service Employees International Union, and other groups said the deal threatens competition in obesity drugs and other gene therapies as Novo would have the ability to prevent rival manufacturers from obtaining Catalent ( CTLT ) services, which will ultimately reduce patient access to treatments.

Novo Nordisk ( NVO ) and Catalent ( CTLT ) did not immediately respond to MTNewswires' request for comment.

Price: 117.31, Change: -0.91, Percent Change: -0.77